In this article, we propose a Bayesian approach to phase I/II dose-finding oncology trials by jointly modeling a binary toxicity outcome and a continuous biomarker expression outcome. We apply our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback